BioSpace News Archive

Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation

TransEnterix, Inc. announced that it plans to release third quarter financial and operating results after the market closes on Thursday, November 5, 2020.

Industry veteran and experienced drug developer Gary D. Glick, Ph.D., named president and chief executive officer

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that the European Commission has granted orphan drug designation for the company’s lead gene therapy candidate PBGM01 for the treatment of GM1 gangliosidosis.

Company Confirms COVID-19 Antibody Home Test and Two Severity Triage Tests can be Submitted to U.S. FDA Under Emergency Use Authorization

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data on the Company’s lead product candidate BDTX-189 at the 32 nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020). “These pre-clinical data demonstrate BDTX-189’s abi

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced today that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 10:00 AM ET. Participating in the KOL Roundtable discussion will be Maurice Zauderer, Ph.D., President and Chief Executive

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for cyclosporine topical ophthalmic emulsion, 0.1% for the treatment of se

Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November 10, 2020, at 4:30 PM Eastern Time. Conference Call Details Tuesday, November 10 , at 4:30 PM Eastern Tim

Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix’s Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company’s Board of Directors effective November 1, 2020